A Phase 2 interventional study of RE104 for Injection in Postpartum Depression, sponsored by Reunion Neuroscience Inc. Completed at 38 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Reunion Neuroscience Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.
Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 101st largest by enrollment of the 198 interventional ones that give a count, is one of 11 that started in 2024, is one of 18 in phase 2, and was the 188th registered.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
Browse Depression, Postpartum studies →38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:
University of South Carolina · Sites in United States
Ages 18+ · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
University of Florida · Sites in United States
Ages 15–49 · Women only
Lipocine Inc. · Sites in United States
Ages 15–45 · Women only
Northwestern University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 20 · Phase 3 14 · Phase 4 7
First in 1996; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Median enrollment 86 across the 198 interventional studies, 175 across the 22 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 220 have an industry lead sponsor. The 10 most frequent:
Reunion Neuroscience Inc is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Reunion Neuroscience Inc has 1 study filed under Depression, Postpartum — fewer than ten, so there is no comparison to draw.
22 of the studies in Depression, Postpartum with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT07822321Phase 3Lipocine Inc.Brexanolone Lifting Outcomes Of Moms | 2027-08 |
| NCT05345834Children's National Research InstituteThe DC Mother-Infant Behavioral Wellness Program | 2026-11-30 |
| NCT06831968University of VirginiaClinical Validation of a Predictive Test for Postpartum Depression | 2026-11-30 |
| NCT06175104Children's Hospital Medical Center, CincinnatiHeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 220 studies in Depression, Postpartum with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single subcutaneous injection of 1.5 mg RE104 for Injection
Drug: RE104 for Injection
A single subcutaneous injection of 30 mg RE104 for Injection
Drug: RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Time frame: Day 1, Day 14 and Day 28
RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS response (≥ 50 percent reduction in score from baseline)
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS remission (score ≤ to 10)
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg Clinical Global Impression-Improvement (CGI-I)
The Clinical Global Impression - Improvement (CGI-I) Scale is a clinician-rated instrument that weighs the clinical impact of the identified symptom(s) on behavior and function and measures changes in psychopathology since the treatment was administered on a scale from 1 (very much improved) to 7 (very much worse).
Time frame: Day 1, Day 7 and Day 28
RE104 30 mg versus RE104 1.5 mg change from baseline in CGI-Severity (CGI-S)
The Clinical Global Impression - Severity Scale is a clinician-rated instrument that grades severity of symptoms on a scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients).
Time frame: Day 1, Day 7 and Day 28
RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.
Time frame: Day 7
RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.
Time frame: From dosing through study completion (post-dose follow-up is for 28 days)
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in May 2025, 11 months.
Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luvesilocin
Reunion Neuroscience Inc